Flow Cytometry Assesses Minimal Residual Disease in Multiple Myeloma

This article originally appeared here.
Share this content:
Flow cytometry is one of several new diagnostic methods useful for recurrence assessment in multiple myeloma.
Flow cytometry is one of several new diagnostic methods useful for recurrence assessment in multiple myeloma.

(HealthDay News) -- Data on methods used for assessing minimal residual disease (MRD) in multiple myeloma (MM) are presented in a report published online Oct. 23 in the International Journal of Laboratory Hematology.

Irina V. Galtseva, from the Ministry of Healthcare of the Russian Federation in Moscow, and colleagues discussed the use of new diagnostic methods for MRD detection in MM.

The researchers note that response to treatment and prediction of recurrence can be assessed more reliably using new diagnostic methods, including allele-specific polymerase chain reaction, new-generation sequencing, and multicolor flow cytometry, which allow detection of MRD with sensitivity of 10−5 to 10 −6. Multiflow cytometry is nonstandardized, and its sensitivity and specificity depend on monoclonal antibody panel, characteristics of flow cytometers, and strategies for gating. Increasing the numbers of antigens analyzed and using at least eight-color flow cytometry enables highly specific and accurate analysis, resulting in sensitivity of about 0.001 percent.

"It has been demonstrated that MRD in MM patients is potentially achievable and is an important independent prognostic factor. Thus, MRD testing is essential in assessing treatment effectiveness at different stages of treatment and in future can help take adequate decisions at the stage of maintenance therapy after HDCT [high-dose chemotherapy] and also design individual treatment protocols," the authors write.

Abstract
Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs